Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44910 | 1.00 | PTGS1 (0.31) | PTGS1AKR1C3APEX1 | |
| Hydrochloric Acid SCHEMBL5177431 | 0.98 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| Acetic Acid SCHEMBL6238307 | 0.98 | FFAR3 (0.32) | PTGS1AKR1C3 | |
| Bromide SCHEMBL1061718 | 0.98 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| Chloromethane SCHEMBL219839 | 0.98 | TUBB1 (0.31) | PTGS1AKR1C3 | |
| Chloromethane SCHEMBL28961622 | 0.96 | TUBB1 (0.30) | — | |
| Chloromethane SCHEMBL28392741 | 0.96 | TUBB1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL10569862 | 0.96 | — | — | |
| Chloromethane SCHEMBL9414319 | 0.96 | TUBB1 (0.30) | — | |
| SCHEMBL5925668 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7322694-B2 | Hybrid contact lens system and method | SYNERGEYES, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20060285072-A1 | Hybrid contact lens system and method | DAHI ALI | 2006-12-21 | — | — | US | claimed |
| US-20060256284-A1 | Hybrid contact lens system and method | DAHI ALI | 2006-11-16 | — | — | US | claimed |
| EP-1714182-A2 | HYBRID CONTACT LENS SYSTEM AND METHOD | Quarter Lambda Technologies Inc. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005079290-A2 | HYBRID CONTACT LENS SYSTEM AND METHOD | SYNERGEYES, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050018130-A1 | Hybrid contact lens system and method | SYNERGEYES, INC. | 2005-01-27 | — | — | US | claimed |
| US-20040179167-A1 | Hybrid contact lens system and method | SYNERGEYES, INC. | 2004-09-16 | — | — | US | claimed |
| EP-0218382-B1 | TREATMENT OF ARCHIVAL MATERIAL | The British Library (GB) | 1989-12-13 | — | — | EP | claimed |
| EP-0155797-B1 | TREATMENT OF ARCHIVAL MATERIAL | The British Library (GB) | 1989-07-26 | — | — | EP | claimed |
| US-11525060-B2 | Near-infrared absorbing composition, optical structure comprising the same, and camera module and electronic device comprising the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-12-13 | — | — | US | disclosed |
| US-20200332132-A1 | NEAR-INFRARED ABSORBING COMPOSITION, OPTICAL STRUCTURE COMPRISING THE SAME, AND CAMERA MODULE AND ELECTRONIC DEVICE COMPRISING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-10-22 | — | — | US | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-7585074-B2 | Hybrid contact lens system and method | SYNERGEYES, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2005079290-A2 | HYBRID CONTACT LENS SYSTEM AND METHOD | SYNERGEYES, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050018130-A1 | Hybrid contact lens system and method | SYNERGEYES, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040212779-A1 | Hybrid contact lens system and method | SYNERGEYES, INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040179167-A1 | Hybrid contact lens system and method | SYNERGEYES, INC. | 2004-09-16 | — | — | US | disclosed |
| US-4994088-A | Amphoteric polymer, water soluble inorganic salt, oil or fat, cationic surfactant, water or aqueous alcohol | KAO CORPORATION (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4987210-A | COMPLEXING IODINE AND WATER-INSOLUBLE DRUGS TO MAKE THEM MORE SOLUBLE | GAF CHEMICALS CORPORATION (US) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | PTGS1 211/4885AKR1C3 1096/4885APEX1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.